July 1, 2026
The panel contrasts FLAURA-2 (osimertinib plus chemotherapy) with MARIPOSA (osimertinib plus amivantamab), acknowledging similar efficacy profiles with overall survival approaching four years in both regimens. However, significant differences exist in toxicity profiles and supportive care requirements.
Related Posts
Optimizing Treatment Selection in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence
Shared Decision-Making and Risk Stratification in EGFR-Mutant NSCLC
TP53 Mutations in EGFR-Mutant and Risk Stratification
